Microbiota intestinal de indivíduos que sofreram acidente ocupacional com materiais biológicos e que realizaram profilaxia anti-retroviral / Intestinal microbiota of individuals who suffered occupational accidents with biological materials and underwent antiretroviral prophylaxis

Avaliar a microbiota intestinal de indivíduos que sofreram acidente ocupacional com materiais biológicos e receberam anti-retrovirais foi o objetivo deste estudo. O grupo de estudo constou de 23 indivíduos com idade entre 18-45 anos, sendo 13 doadores de sangue e 10 que sofreram acidente ocupacional. Foram avaliados a microbiota intestinal, antropometria e exames laboratoriais pré, pós e 30 dias após o término da medicação. Zidovudina mais lamivudina foi utilizada em 70 por cento dos indivíduos associado ao nelfinavir, 20 por cento ao efavirenz e 10 por cento ao ritonavir. As alterações nutricionais e dietéticas-laboratoriais e de microbiota intestinal foram analisadas em três momentos. M1: até dois dias do início da profilaxia; M2: no último dia da profilaxia e M3: 30 dias após o término da profilaxia. Náuseas, vômitos e diarréia estiveram presentes em 50 por cento no segundo momento do estudo. Sobrepeso em 70 por cento, desnutrição e eutrofia em 10 por cento, dos indivíduos, não se modificaram durante o estudo. Transaminases, triglicérides, LDL-colesterol se elevaram no segundo momento e normalizaram 30 dias após término da medicação. Houve redução significativa dos Lactobacillus, Bifidobacterium e Bacteróides nos três momentos. Uso de anti-retrovirais provocou impacto significativo na microbiota intestinal dos indivíduos, sem recuperação em 30 dias.

The aim of this study was to evaluate the intestinal microbiota of individuals who had suffered occupational accidents and had received antiretrovirals. The study group consisted of 23 individuals between 18 and 45 years old, of whom 13 were blood donors and 10 had suffered occupational accidents. Intestinal microflora, anthropometry and laboratory tests were evaluated before, after and 30 days after discontinuation of the medication. Zidovudine plus lamivudine was used in association with nelfinavir for 70 percent of the individuals, with efavirenz for 20 percent and with ritonavir for 10 percent. Nutritional, diet, laboratory and intestinal microbiota abnormalities were analyzed at three times: M1, not more than two days after starting prophylaxis; M2, on the last day of prophylaxis; and M3, 30 days after ending prophylaxis. Nausea, vomiting and diarrhea were present in 50 percent at M2. Overweight in 70 percent, malnutrition and eutrophy in 10 percent of the individuals remained unchanged during the study. Transaminases, triglycerides and LDL-cholesterol because elevated at M2 and normalized 30 days after discontinuation of the medication. There were significant reductions in Lactobacillus, Bifidobacterium and Bacteroides at the three times. The use of antiretrovirals caused a significant impact on the individuals’ intestinal microbiota, without recovery after 30 days.

Bezafibrate for the treatment of hypertriglyceridemia in HIV1-infected patients on highly active antiretroviral therapy

The use of highly active antiretroviral therapy (HAART) in HIV-infected patients has been associated with the development of risk factors for cardiovascular diseases (CD) including dyslipidemia and insulin resistance, hypertriglyceridemia being the most frequent metabolic disturbance in these patients. Fibrates are indicated when hypertriglyceridemia is accentuated and persists for over six months. We evaluated the efficacy and safety of bezafibrate for the treatment of hypertriglyceridemia in HIV-infected individuals on HAART. All patients received 400mg/day of bezafibrate and were evaluated three times: Mo (pre-treatment), M1 (one month after treatment), and M2 (six months after treatment). Fifteen adult individuals, eight males and seven females with mean age = 41.2 ± 7.97 years and triglyceride serum levels > 400mg/dL were included in the study. Smoking, alcohol ingestion and sedentarism rates were 50 percent, 6.66 percent and 60 percent, respectively. Family history of CD, hypertension and diabetes mellitus was reported in 33.3 percent, 40 percent and 46.7 percent of the cases, respectively, while dyslipidemia was reported by only 13.3 percent. More than half of the patients were using a protease inhibitor plus a nucleotide analog transcriptase inhibitor. Eutrophy and tendency toward overweight were observed at all three study time points. There were significant reductions in triglyceride serum levels from Mo to M1 and from Mo to M2. No significant changes were observed in the serum levels of creatine phosphokinase, hepatic enzymes, CD4+, CD8+ and viral load. Therefore, bezafibrate seems to be safe and effective for the reduction of hypertriglyceridemia in HIV-infected patients on HAART.